Search

Your search keyword '"Mitchell, Claire L."' showing total 30 results
Start Over Author "Mitchell, Claire L."
30 results on '"Mitchell, Claire L."'

1. Customized Mid-Air Gestures for Accessibility: A $B Recognizer for Multi-Dimensional Biosignal Gestures

Author

Yamagami, Momona, Mitchell, Claire L., Portnova-Fahreeva, Alexandra A., Kong, Junhan, Mankoff, Jennifer, and Wobbrock, Jacob O.

Subjects
Computer Science - Human-Computer Interaction
Abstract

Biosignal interfaces, using sensors in, on, or around the body, promise to enhance wearables interaction and improve device accessibility for people with motor disabilities. However, biosignals are multi-modal, multi-dimensional, and noisy, requiring domain expertise to design input features for gesture classifiers. The \$B-recognizer enables mid-air gesture recognition without needing expertise in biosignals or algorithms. \$B resamples, normalizes, and performs dimensionality reduction to reduce noise and enhance signals relevant to the recognition. We tested \$B on a dataset of 26 participants with and 8 participants without upper-body motor disabilities performing personalized ability-based gestures. For two conditions (user-dependent, gesture articulation variability), \$B outperformed our comparison algorithms (traditional machine learning with expert features and deep learning), with > 95% recognition rate. For the user-independent condition, \$B and deep learning performed comparably for participants with disabilities. Our biosignal dataset is publicly available online. $B highlights the potential and feasibility of accessible biosignal interfaces., Comment: 20 pages, 7 figures, 1 table

Published
2024

2. Ability-Based Methods for Personalized Keyboard Generation

Author

Mitchell, Claire L., Cler, Gabriel J., Fager, Susan K., Contessa, Paola, Roy, Serge H., De Luca, Gianluca, Kline, Joshua C., and Vojtech, Jennifer M.

Subjects
Computer Science - Human-Computer Interaction
Abstract

This study introduces an ability-based method for personalized keyboard generation, wherein an individual's own movement and human-computer interaction data are used to automatically compute a personalized virtual keyboard layout. Our approach integrates a multidirectional point-select task to characterize cursor control over time, distance, and direction. The characterization is automatically employed to develop a computationally efficient keyboard layout that prioritizes each user's movement abilities through capturing directional constraints and preferences. We evaluated our approach in a study involving 16 participants using inertial sensing and facial electromyography as an access method, resulting in significantly increased communication rates using the personalized keyboard (52.0 bits/min) when compared to a generically optimized keyboard (47.9 bits/min). Our results demonstrate the ability to effectively characterize an individual's movement abilities to design a personalized keyboard for improved communication. This work underscores the importance of integrating a user's motor abilities when designing virtual interfaces., Comment: 20 pages, 7 figures

Published
2022
Full Text
View/download PDF

4. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Published
2020
Full Text
View/download PDF

6. Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

9. Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

10. Real-World Concordance between Germline and Tumour BRCA1/2 Status in Epithelial Ovarian Cancer.

Author

Morgan, Robert D., Burghel, George J., Schlecht, Helene, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Salih, Zena, Shaw, Joseph, Desai, Sudha, Jayson, Gordon C., Woodward, Emma R., and Evans, D. Gareth R.

Subjects
GENETIC mutation, SEQUENCE analysis, SPECIALTY hospitals, DNA, BRCA genes, OVARIAN epithelial cancer, AGE distribution, GENETIC testing, MOLECULAR pathology, CANCER patients, CANCER treatment, STEM cells, DESCRIPTIVE statistics, RESEARCH funding, NUCLEIC acid amplification techniques
Abstract

Simple Summary: Approximately 10–15% of patients with epithelial ovarian cancer have an inherited (germline) BRCA1 or BRCA2 mutation. Following a diagnosis of epithelial ovarian cancer, patients are routinely tested for germline and/or somatic (tumour) BRCA1/2 mutations. Our study shows that if germline BRCA1/2 testing is only performed for patients with a positive tumour BRCA1/2 test result, and tumour testing is performed using Myriad's myChoice® companion diagnostic, a proportion of germline BRCA1/2 large rearrangements could be missed. If paired germline-tumour DNA testing is not possible for all patients, our data shows that it would be appropriate to test all patients with epithelial ovarian cancer aged < 79 years old for germline BRCA1/2 mutations, regardless of the tumour BRCA1/2 result, whilst only needing to test patients aged ≥ 80 years old for a germline BRCA1/2 mutation if they have a positive tumour BRCA1/2 result. Patients diagnosed with epithelial ovarian cancer may undergo reflex tumour BRCA1/2 testing followed by germline BRCA1/2 testing in patients with a positive tumour test result. This testing model relies on tumour BRCA1/2 tests being able to detect all types of pathogenic variant. We analysed germline and tumour BRCA1/2 test results from patients treated for epithelial ovarian cancer at our specialist oncological referral centre. Tumour BRCA1/2 testing was performed using the next-generation sequencing (NGS)-based myChoice® companion diagnostic (CDx; Myriad Genetics, Inc.). Germline BRCA1/2 testing was performed in the North West Genomic Laboratory Hub using NGS and multiplex ligation-dependent probe amplification. Between 11 April 2021 and 11 October 2023, 382 patients were successfully tested for tumour BRCA1 and BRCA2 variants. Of these, 367 (96.1%) patients were tested for germline BRCA1/2 variants. In those patients who underwent tumour and germline testing, 15.3% (56/367) had a BRCA1/2 pathogenic variant (36 germline and 20 somatic). All germline BRCA1/2 pathogenic small sequencing variants were detected in tumour DNA. By contrast, 3 out of 8 germline BRCA1/2 pathogenic large rearrangements were not reported in tumour DNA. The overall concordance of germline BRCA1/2 pathogenic variants detected in germline and tumour DNA was clinically acceptable at 91.7% (33/36). The myChoice® CDx was able to detect most germline BRCA1/2 pathogenic variants in tumour DNA, although a proportion of pathogenic large rearrangements were not reported. If Myriad's myChoice® CDx is used for tumour BRCA1/2 testing, our data supports a testing strategy of germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, with germline BRCA1/2 testing only necessary for patients aged ≥ 80 years old with a tumour BRCA1/2 pathogenic variant. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

12. CCR Translation for the Article from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data from Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., primary, Clamp, Andrew R., primary, Ross, Jed, primary, Ho, Calvin C.K., primary, Jackson, Alan, primary, Parker, Geoff J.M., primary, Rose, Chris J., primary, Peale, Franklin V., primary, Friesenhahn, Michel, primary, Mitchell, Claire L., primary, Watson, Yvonne, primary, Roberts, Caleb, primary, Hope, Lynn, primary, Cheung, Sue, primary, Reslan, Hani Bou, primary, Go, Mary Ann T., primary, Pacheco, Glenn J., primary, Wu, Xiumin, primary, Cao, Tim C., primary, Ross, Sarajane, primary, Buonaccorsi, Giovanni A., primary, Davies, Karen, primary, Hasan, Jurjees, primary, Thornton, Paula, primary, del Puerto, Olivia, primary, Ferrara, Napoleone, primary, van Bruggen, Nicholas, primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

14. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., additional, White, Daniel J., additional, Price, Marcus, additional, Burghel, George J., additional, Ryder, W. David J., additional, Mahmood, Reem D., additional, Murphy, Alexander D., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Wheeler, Chelsey, additional, Buckley, Emma, additional, Truelove, Joanna, additional, King, Georgia, additional, Ainaoui, Yasmina, additional, Bhaskar, Sanjeev S., additional, Shaw, Joseph, additional, Evans, D. Gareth R., additional, Kilerci, Bedirhan, additional, Pearce, Simon P., additional, Brady, Gerard, additional, Dive, Caroline, additional, O'Connor, James P.B., additional, Wallace, Andrew J., additional, Rothwell, Dominic G., additional, Edmondson, Richard J., additional, and Jayson, Gordon C., additional

Published
2023
Full Text
View/download PDF

15. Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

Author

Morgan, Robert D., primary, Burghel, George J., additional, Flaum, Nicola, additional, Bulman, Michael, additional, Smith, Philip, additional, Clamp, Andrew R., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Woodward, Emma R., additional, Lalloo, Fiona, additional, Crosbie, Emma J., additional, Edmondson, Richard J., additional, Schlecht, Helene, additional, Jayson, Gordon C., additional, and Evans, D. Gareth R., additional

Published
2023
Full Text
View/download PDF

19. Defective importin [beta] recognition and nuclear import of the sex-determining factor SRY are associated with XY sex-reversing mutations

Author

Harley, Vincent R., Layfield, Sharon, Mitchell, Claire L., Forwood, Jade K., John, Anna P., Briggs, Lyndall J., McDowall, Sharon G., and Jans, David A.

Subjects
Sex determination, Genetic -- Research, Science and technology, National Academy of Sciences -- Research
Abstract

The architectural transcription factor SRY (sex-determining region of the Y chromosome) plays a key role in sex determination as indicated by the fact that mutations in SRY are responsible for XY gonadal dysgenesis in humans. Although many SRY mutations reduce DNA-binding/bending activity, it is not clear how SRY mutations that do not affect interaction with DNA contribute to disease. The SRY high-mobility group domain harbors two nuclear localization signals (NLSs), and here we examine SRY from four XY females with missense mutations in these signals. In all cases, mutant SRY protein is partly localized to the cytoplasm, whereas wild-type SRY is strictly nuclear. Each NLS can independently direct nuclear transport of a carrier protein in vitro and in vivo, with mutations in either affecting the rate and extent of nuclear accumulation. The N-terminal NLS function is independent of the conventional NLS-binding importins (IMPs) and requires unidentified cytoplasmic transport factors, whereas the C-terminal NLS is recognized by IMP[beta]. The SRY-R133W mutant shows reduced IMP[beta] binding as a direct consequence of the sex-reversing C-terminal NLS mutation. Of the N-terminal NLS mutants examined, SRY-R62G unexpectedly shows a marked reduction in IMP[beta] binding, whereas SRY-R75N and SRY-R76P show normal IMP[beta] binding, suggesting defects in the IMP-independent pathway. We conclude that SRY normally requires the two distinct NLS-dependent nuclear import pathways to reach sufficient levels in the nucleus for sex determination. This study documents cases of human disease being explained, at a molecular level, by the impaired ability of a protein to accumulate in the nucleus.

Published
2003

21. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases

Author

Morgan, Robert D, primary, Burghel, George J, additional, Flaum, Nicola, additional, Bulman, Michael, additional, Clamp, Andrew R, additional, Hasan, Jurjees, additional, Mitchell, Claire L, additional, Schlecht, Helene, additional, Woodward, Emma R, additional, Lallo, Fiona I, additional, Crosbie, Emma J, additional, Edmondson, Richard J, additional, Wallace, Andrew J, additional, Jayson, Gordon C, additional, and Evans, D Gareth R, additional

Published
2019
Full Text
View/download PDF

22. Mainstreaming germline BRCA1/2testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Abstract

Poly(ADP-ribose) polymerase (PARP) inhibitors improve survival in BRCA-mutant high-grade serous ovarian carcinoma. As a result, germline and somatic BRCA1/2testing has become standard practice in women diagnosed with ovarian cancer. We outline changes in testing and detection rates of germline BRCA1/2pathogenic variants (PVs) in cases of non-mucinous epithelial ovarian cancer diagnosed during three eras, spanning 12 years, within the North West of England, and compare the uptake of cascade testing in families identified by oncology-led mainstreaming versus regional genetics clinics. Eras included: Period 1 (20% risk threshold for testing): between January 2007 and May 2013; Period 2 (10% risk threshold for testing): between June 2013 and October 2017 and; Period 3 (mainstream testing): between November 2017 and November 2019. A total of 1081 women underwent germline BRCA1/2testing between January 2007 and November 2019 and 222 (20.5%) were found to have a PV. The monthly testing rate increased by 3.3-fold and 2.5-fold between Periods 1–2 and Periods 2–3, respectively. A similar incidence of germline BRCA1/2PVs were detected in Period 2 (17.2%) and Period 3 (18.5%). Uptake of cascade testing from first-degree relatives was significantly lower in those women undergoing mainstream testing compared with those tested in regional genetics clinics (31.6% versus 47.3%, P= 0.038). Mainstream testing allows timely detection of germline BRCA1/2status to select patients for PARP inhibitors, but shortfalls in the uptake of cascade testing in first-degree relatives requires optimisation to broaden benefits within families.

Published
2020
Full Text
View/download PDF

23. Prevalence of germline pathogenic BRCA1/2variants in sequential epithelial ovarian cancer cases

Author

Morgan, Robert D, Burghel, George J, Flaum, Nicola, Bulman, Michael, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire L, Schlecht, Helene, Woodward, Emma R, Lallo, Fiona I, Crosbie, Emma J, Edmondson, Richard J, Wallace, Andrew J, Jayson, Gordon C, and Evans, D Gareth R

Abstract

IntroductionPoly(ADP-ribose) polymerase inhibitors significantly improve progression-free survival in platinum-sensitive high-grade serous and endometrioid ovarian carcinoma, with greatest benefits observed in women with a pathogenic BRCA1/2variant. Consequently, the demand for germline BRCA1/2testing in ovarian cancer has increased substantially, leading to the screening of unselected populations of patients. We aimed to determine the prevalence of pathogenic germline BRCA1/2variants in women diagnosed with epithelial ovarian cancer, categorised according to the established risk factors for hereditary breast and ovarian cancer syndrome and the Manchester BRCA Score, to inform risk stratification.MethodsA cohort of sequential epithelial ovarian cancer cases recruited between June 2013 and September 2018 underwent germline BRCA1/2testing by next-generation sequencing and multiplex ligation-dependent probe amplification.ResultsFive hundred and fifty-seven patients were screened. Of these, 18% had inherited a pathogenic BRCA1/2variant. The prevalence of pathogenic BRCA1/2variants was >10% in women diagnosed with ovarian cancer earlier than 60 years of age (21%) and those diagnosed later than 60 years of age with a family history of breast and/or ovarian cancer (17%) or a medical history of breast cancer (34%). The prevalence of pathogenic BRCA1/2variants was also >10% in women with a Manchester BRCA Score of ≥15 points (14%).DiscussionOur study suggests that age at diagnosis, family history of breast and/or ovarian cancer, medical history of breast cancer or a Manchester BRCA Score of ≥15 points are associated with a >10% prevalence of germline pathogenic BRCA1/2variants in epithelial ovarian cancer.

Published
2019
Full Text
View/download PDF

26. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

Author

Mitchell, Claire L., primary, O’Connor, J. P. B., additional, Roberts, C., additional, Watson, Y., additional, Jackson, A., additional, Cheung, S., additional, Evans, J., additional, Spicer, J., additional, Harris, A., additional, Kelly, C., additional, Rudman, S., additional, Middleton, M., additional, Fielding, A., additional, Tessier, J., additional, Young, H., additional, Parker, G. J. M., additional, and Jayson, G. C., additional

Published
2010
Full Text
View/download PDF

27. Preliminary Study of Oxygen-Enhanced Longitudinal Relaxation in MRI: A Potential Novel Biomarker of Oxygenation Changes in Solid Tumors

Author

O'Connor, James P.B., primary, Naish, Josephine H., additional, Parker, Geoff J.M., additional, Waterton, John C., additional, Watson, Yvonne, additional, Jayson, Gordon C., additional, Buonaccorsi, Giovanni A., additional, Cheung, Sue, additional, Buckley, David L., additional, McGrath, Deirdre M., additional, West, Catharine M.L., additional, Davidson, Susan E., additional, Roberts, Caleb, additional, Mills, Samantha J., additional, Mitchell, Claire L., additional, Hope, Lynn, additional, Ton, N. Chan, additional, and Jackson, Alan, additional

Published
2009
Full Text
View/download PDF

28. Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

Author

O'Connor, James P.B., primary, Carano, Richard A.D., additional, Clamp, Andrew R., additional, Ross, Jed, additional, Ho, Calvin C.K., additional, Jackson, Alan, additional, Parker, Geoff J.M., additional, Rose, Chris J., additional, Peale, Franklin V., additional, Friesenhahn, Michel, additional, Mitchell, Claire L., additional, Watson, Yvonne, additional, Roberts, Caleb, additional, Hope, Lynn, additional, Cheung, Sue, additional, Reslan, Hani Bou, additional, Go, Mary Ann T., additional, Pacheco, Glenn J., additional, Wu, Xiumin, additional, Cao, Tim C., additional, Ross, Sarajane, additional, Buonaccorsi, Giovanni A., additional, Davies, Karen, additional, Hasan, Jurjees, additional, Thornton, Paula, additional, del Puerto, Olivia, additional, Ferrara, Napoleone, additional, van Bruggen, Nicholas, additional, and Jayson, Gordon C., additional

Published
2009
Full Text
View/download PDF

29. Enhancing Fraction Predicts Clinical Outcome following First-Line Chemotherapy in Patients with Epithelial Ovarian Carcinoma

Author

O'Connor, James P.B., primary, Jayson, Gordon C., additional, Jackson, Alan, additional, Ghiorghiu, Dana, additional, Carrington, Bernadette M., additional, Rose, Chris J., additional, Mills, Samantha J., additional, Swindell, Ric, additional, Roberts, Caleb, additional, Mitchell, Claire L., additional, and Parker, Geoffrey J.M., additional

Published
2007
Full Text
View/download PDF

30. Ability-based Keyboards for Augmentative and Alternative Communication: Understanding How Individuals' Movement Patterns Translate to More Efficient Keyboards: Methods to Generate Keyboards Tailored to User-specific Motor Abilities.

Author

Mitchell CL, Cler GJ, Fager SK, Contessa P, Roy SH, De Luca G, Kline JC, and Vojtech JM

Abstract

This study presents the evaluation of ability-based methods extended to keyboard generation for alternative communication in people with dexterity impairments due to motor disabilities. Our approach characterizes user-specific cursor control abilities from a multidirectional point-select task to configure letters on a virtual keyboard based on estimated time, distance, and direction of movement. These methods were evaluated in three individuals with motor disabilities against a generically optimized keyboard and the ubiquitous QWERTY keyboard. We highlight key observations relating to the heterogeneity of the manifestation of motor disabilities, perceived importance of communication technology, and quantitative improvements in communication performance when characterizing an individual's movement abilities to design personalized AAC interfaces.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results